Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TACR2 | P21452 | 3/20 | 0.40 |
| ▸ | TACR1 | P25103 | 6/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | PSMB8 | P28062 | 3/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.35 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.35 |
| ▸ | TMPRSS11D | O60235 | 1/20 | 0.35 |
| ▸ | CTRL | P40313 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.35 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.35 |
| ▸ | PSMD11 | O00231 | 1/20 | 0.35 |
| ▸ | PSMD12 | O00232 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6800005 | 0.92 | USP2 (0.40) | USP2HTTTACR2MEN1ALDH1A1 | |
| SCHEMBL6506254 | 0.88 | ELANE (0.41) | TACR1HPGDELANE | |
| SCHEMBL6806031 | 0.84 | PSMB8 (0.42) | USP2HTTTACR2PSMB8ELANE | |
| SCHEMBL7444707 | 0.83 | ELANE (0.39) | TACR1MEN1KMT2AELANECTSB | |
| SCHEMBL6800996 | 0.82 | ELANE (0.41) | TACR1ALDH1A1HPGDELANE | |
| SCHEMBL6801500 | 0.81 | ELANE (0.42) | TACR1MEN1HPGDKMT2AELANE | |
| SCHEMBL6507241 | 0.81 | ELANE (0.40) | TACR1ELANE | |
| SCHEMBL6505024 | 0.80 | ELANE (0.40) | TACR1MEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL6498961 | 0.78 | ELANE (0.39) | TACR1MEN1KMT2APSMB8ELANE | |
| SCHEMBL6806041 | 0.77 | ELANE (0.40) | TACR1HPGDKMT2AELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6683077-B2 | 4H-3,1-BENZOXAZIN-4-ONE COMPOUNDS OF GIVEN FORMULA; HERPES INFECTIONS; ASSEMBLIN PROTEASE INHIBITORS | G.D. SEARLE & CO. | 2004-01-27 | — | — | US | claimed |
| US-20030022895-A1 | 2-Amino-benzoxazinones for the treatment of viral infections | G.D. SEARLE & CO. | 2003-01-30 | — | — | US | claimed |
| EP-0828721-B1 | 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS | SEARLE & CO (US) | 2001-11-14 | — | — | EP | claimed |
| WO-1996037485-A1 | 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS | G.D. SEARLE & CO. (US) | 1996-11-28 | — | — | WO | claimed |
| US-20050032793-A1 | 2-amino-benzoxazinones for the treatment of viral infections | G.D. SEARLE & CO. (US) | 2005-02-10 | — | — | US | disclosed |
| US-6683077-B2 | 4H-3,1-BENZOXAZIN-4-ONE COMPOUNDS OF GIVEN FORMULA; HERPES INFECTIONS; ASSEMBLIN PROTEASE INHIBITORS | G.D. SEARLE & CO. | 2004-01-27 | — | — | US | disclosed |
| US-20030022895-A1 | 2-Amino-benzoxazinones for the treatment of viral infections | G.D. SEARLE & CO. | 2003-01-30 | — | — | US | disclosed |
| US-6380189-B1 | FOR TREATING HERPES-RELATED DISORDERS | G.D. SEARLE & CO. | 2002-04-30 | — | — | US | disclosed |
| EP-0828721-B1 | 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS | SEARLE & CO (US) | 2001-11-14 | — | — | EP | disclosed |
| EP-1122245-A2 | 2-Amino-benzoxazinones for the treatment of viral infections | G.D. Searle & Co. (US) | 2001-08-08 | — | — | EP | disclosed |
| WO-1996037485-A1 | 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS | G.D. SEARLE & CO. (US) | 1996-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022895-A1 | 2-Amino-benzoxazinones for the treatment of viral infections | IFNAR1, IL4I1, HAX1 | USP2 3103/4885HTT 4033/4885TACR2 2505/4885 |
| US-20050032793-A1 | 2-amino-benzoxazinones for the treatment of viral infections | IFNAR1, IL4I1, ACE2 | USP2 2593/4885HTT 3717/4885TACR2 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.